Industry

Wejo RTTI™ will provide 9-1-1 first responders access to real-time comprehensive traffic data from millions of connected vehicles through Roadside Telematics Corp’s RoadMedic® Next-Generation 9-1-1 Intelligent Crash Data Ecosystem. MANCHESTER, England–(BUSINESS WIRE)–Wejo Group Limited (NASDAQ: WEJO), a global leader in Smart Mobility cloud and software solutions for connected, electric and autonomous vehicle data, today announced … [Read more…]

WOBURN, Mass.–(BUSINESS WIRE)–Covaris, LLC (“Covaris” or “the Company”), a manufacturer of advanced tools enabling life science innovations, announced today that it has appointed Annemarie Watson as Chief Executive Officer, effective immediately. Ms. Watson succeeds Covaris founder Jim Laugharn, who will remain an investor in Covaris and on serve on the Company’s Board of Directors, as … [Read more…]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–$AVRO—AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences: Hybrid BTIG Biotechnology Conference 2022 Dates: Monday, Aug. 8, 2022 – Tuesday, … [Read more…]

Pivotal study follows successful Phase 2 trial, which demonstrated improvements in attention function as compared to both treatment as usual and single task video game groups Pivotal Data Readout expected in 2H2023 BOSTON–(BUSINESS WIRE)–Akili Interactive (“Akili”), a leading digital medicine company, today announced the start of a pivotal Phase 3 randomized, controlled study of SDT-001 … [Read more…]

DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2022 and provide a business update on August 8, 2022. About Precision BioSciences, Inc. Precision BioSciences, Inc. … [Read more…]

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal third quarter ended June 30, 2022 after the U.S. market closes on August 8, 2022. Enanta management will host … [Read more…]

Omnipod 5 is Now Fully Available through Retail Pharmacy Channels ACTON, Mass.–(BUSINESS WIRE)–Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Omnipod® 5 Automated Insulin Delivery (AID) System (Omnipod 5) is now fully available through U.S. retail pharmacy channels … [Read more…]

DESHLER, Ohio–(BUSINESS WIRE)–#flowerpollenextract–Graminex®, L.L.C. is pleased to announce it has completed a clinical study with Graminex® Flower Pollen Extract for women’s urinary incontinence and urinary health with positive results. This study was conducted as a randomized, double-blind, placebo-controlled, study to investigate the effectiveness of Graminex® Flower Pollen Extracts in 190 healthy women with urinary incontinence. … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Selective estrogen receptor degraders – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering. This “Selective Estrogen Receptor Degraders – Pipeline Insight, 2022” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in the Selective Estrogen Receptor Degraders pipeline landscape. It covers the pipeline drug profiles, including clinical and … [Read more…]

FORT WORTH, Texas–(BUSINESS WIRE)–NanOlogy LLC, a clinical-stage interventional oncology drug company, announced today that results from a clinical trial of Large Surface Area Microparticle Docetaxel (LSAM-DTX) in High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) have been published in The Journal of Urology®. The research article entitled Phase 1/2 Trial Results of a Large Surface Area Microparticle … [Read more…]